Sort   by:  
 Page size 
0
UnknownEpigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.
Not available
S-EPMC5754782 | biostudies-literature
0
UnknownDFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.
Not available
S-EPMC6606334 | biostudies-literature
0
UnknownTHE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview.
Not available
S-EPMC5650665 | biostudies-literature
0
UnknownDevelopment and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Not available
S-EPMC5408574 | biostudies-literature
0
UnknownAntiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.
Not available
S-EPMC4481320 | biostudies-literature
0
UnknownTwelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Not available
S-EPMC4481318 | biostudies-literature
0
UnknownIdentification of seven new prostate cancer susceptibility loci through a genome-wide association study.
Not available
S-EPMC2846760 | biostudies-literature
0
UnknownGene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
Not available
S-EPMC5379914 | biostudies-literature
0
UnknownMultiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.
Not available
S-EPMC4572072 | biostudies-literature
Sort   by:  
 Page size